Evaluation of the 13C-triolein breath test for fat malabsorption in adult patients with cystic fibrosis.
OBJECTIVE
A simple non-invasive test not requiring the use of radioactive isotopes is required to assess fat malabsorption in adult cystic fibrosis (CF) patients. Breath tests using substrates labeled with 13C meet these conditions. The 14C-triolein breath test is sensitive and specific for measuring fat malabsorption, but involves radiation exposure. The aim of this study was to examine the utility of a test using a 13C label and to determine whether pancreatic replacement therapy would return the test to the values of a normal control group.


METHODS
13CO2 recovery was assessed after an overnight fast in six adult patients with CF, both with and without pancreatic enzyme replacement therapy (PERT) in the usual dose for a light snack, in a randomized order, on different days. Studies were also performed in eight healthy volunteers after oral ingestion. Subjects drank 50 mL of a liquid meal mixed with 200 microL 13C-triolein and breath samples were collected by blowing through a straw into collection tubes every 30 min for 6 h. The effect of gastric emptying was assessed by comparison of oral ingestion with intraduodenal infusion. Intra-individual variability was assessed in nine volunteers by repeating the breath test after drinking the test meal on a separate day.


RESULTS
Compared with healthy subjects there was virtually no recovery of 13CO2 in CF patients without PERT. The median (interquartile range) cumulative percentage dose recovery (cPDR) at 6 h was 3% (0-8) in CF patients compared with 28% (22-41) in healthy controls (P < 0.01). Fat absorption was normalized (37%) (36-43) after ingestion of PERT. Gastric emptying delayed the peak in 13CO2 recovery, but there was no difference in the cPDR at 6 h. There was no difference in recovery between days 1 and 2.


CONCLUSIONS
The 13C-triolein breath test is a simple and reproducible method to measure fat malabsorption. The test provides a screening technique for fat malabsorption in adult CF patients and may be useful for monitoring the lowest effective dose of PERT.
Ritz
Marc A
MA
Gastrointestinal Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Fraser
Robert J
RJ
Di Matteo
Addolorata C
AC
Greville
Hugh
H
Butler
Ross
R
Cmielewski
Patricia
P
Davidson
Geoff
G
D000284:Administration, Oral; D000328:Adult; D001944:Breath Tests / Q000379:methods; D002247:Carbon Isotopes; D018592:Cross-Over Studies; D003550:Cystic Fibrosis / Q000150:complications*; D004041:Dietary Fats / Q000008:administration & dosage / Q000378:metabolism*; D004386:Duodenum; D057487:Enzyme Therapy; D005260:Female; D005746:Gastric Emptying; D006801:Humans; D008286:Malabsorption Syndromes / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000201:enzymology; D014304:Triolein / Q000008:administration & dosage
D002247:Carbon Isotopes; D004041:Dietary Fats; D014304:Triolein